L. Trentmann

Real‐world effectiveness of vedolizumab compared to anti‐TNF agents in biologic‐naïve patients with ulcerative colitis: A two‐year propensity‐score‐adjusted analysis from the prospective, observational VEDOIBD‐study

R. di Giuseppe, R. Ehehalt, S. Plachta-Danielzik, 2023, Alimentary pharmacology & therapeutics.

Su1515: EFFECT OF VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND 1-YEAR EFFECTIVENESS IN COMPARISON TO ANTI-TNF THERAPY IN BIOLOGIC-NAÏVE CROHN'S DISEASE PATIENTS WITH PROPENSITY SCORE ADJUSTMENT: RESULTS OF THE VEDOIBD STUDY

R. Atreya, N. Teich, R. Ehehalt, 2022, Gastroenterology.

Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.

R. Atreya, R. di Giuseppe, R. Ehehalt, 2023, Inflammatory bowel diseases.